Please assess the completion status of the following clinical trial:

Trial Title: Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 and \< 80~2. Type I or Type II Diabetes Mellitus~3. Stable ACE or ARB therapy for 4 weeks prior to study enrollment~4. Urinary protein \> 3000 mg/24 hrs~5. Patients with more than one protein lowering agent (e.g. ACE or ARB, or MR antagonist or Tekturna require two consecutive 24 hour urinary protein of 2000 mg/24 hrs.~Exclusion Criteria:~1. Age \<18 or \>80~2. HgbA1c \> 9.0% or 11% if using the (DCCT / NGSP) method.~3. eGFR \< 20 mls/min by MDRD formula or eGFR by (Cockoff-Gault 20 mls/min)~4. Dilated cardiomyopathy with known EF \< 40%~5. Pregnant or nursing mothers~6. Patients with an admission for diabetic ketoacidosis, or non-ketotic hyperosmolar coma within 6 months of study enrollment.~7. Patients with known mixed glomerulonephritis and diabetic glomerulopathy~8. Patients within 3 mths of operative procedures or chronic non-healing wounds~9. Patients with glucocorticoid-induced diabetes mellitus~10. Patients with known sensitivity to porcine protein products~11. Patients with bleeding gastric or duodenal ulcers requiring hospitalization six months prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ACTH-16 units (Type: ACTIVE_COMPARATOR): Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
- ACTH-32 units (Type: ACTIVE_COMPARATOR): Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.

Based on this trial design, predict the completion outcome and termination type (if applicable).